Buspirone augmentation of fluoxetine in obsessive-compulsive disorder.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 2188516.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Eleven obsessive-compulsive patients underwent a prospective open-label trial of fluoxetine monotherapy followed by buspirone augmentation. The combination therapy was statistically superior to fluoxetine monotherapy. The results point to the importance of the 5-HT1a receptor in obsessive-compulsive disorder.
Medical subject headings
- Buspirone
- Fluoxetine
- Obsessive-Compulsive Disorder